Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

REPO4EU Precision drug REPurpOsing For EUrope and the world

Coordinator
Universiteit Maastricht, Netherlands
Runs
1 September 2022 to 31 August 2029
Status
Running
EU funding
€23.0m
Total cost
€23.0m
Partners
29 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101057619

What the project is doing

In the project's own words, from its summary on CORDIS.

Here we, a group of long-standing collaborators in innovative drug repurposing, propose to build REPO4EU, a comprehensive European/global platform for validated precision drug repurposing open to stakeholders for information, multimedia training, matchmaking and cooperation. Drug repurposing reduces the time and costs of drug development but is often serendipitous and less effective than classical drug discovery. Both, discovery and repurposing, suffer from the same knowledge gap that diseases are mechanistically not understood and treated symptomatically in an imprecise manner.

Our team of world-leading scientists overcome this by breakthroughs in advanced bioinformatics and artificial intelligence (AI) on real-world big data to redefine diseases in a mechanism-based manner. Patients are still identified by symptom, but stratified according to causal mechanism, the endotype. Trials are small, precise, innovatively designed, prioritising, in coordination with regulators, payers and investors, patient-defined outcomes with high safety and operational excellence.

This revolutionary new era of medicine will allow unprecedented efficacy and cost-effectiveness. The promiscuity of small molecules and recently expanded knowledge of protein structures are exploited by cheminformatics and deep learning to repurpose drugs beyond their original target. At any level of the development chain, even for classic projects, REPO4EU provides expertise and matchmaking for freedom-to-operate, intellectual property, reformulation and value-creation, specialised in drug repurposing.

Within 5 years, REPO4EU will establish a first-in-class coherent and innovative web-based platform for safe and efficient drug repurposing for all types of high unmet medical need indications to all European researchers and SMEs with a unique Open Science concept, ensuring global medical impact. Finally, within a 2-year interphase, REPO4EU will be converted into a sustainable European infrastructure.

Who is involved

OrganisationCityCountryRole
Universiteit MaastrichtMaastrichtNetherlandsCoordinator
Mucke HermannWienAustriaParticipant
Research Institute AG & Co KgWienAustriaParticipant
Universitat WienWienAustriaParticipant
Biolizard NVGentBelgiumParticipant
Universitat ZurichZurichSwitzerlandAssociatedpartner
Concentris Research Management GmbHFurstenfeldbruckGermanyParticipant
Dihesys Digital Health Systems GmbHSchwabisch GmundGermanyParticipant
Genesurge GmbHMunchenGermanyParticipant
Invicol GmbHBerlinGermanyParticipant
Scienceopen GmbHBerlinGermanyParticipant
Sciomics GmbHNeckargemundGermanyParticipant
Technische Universitaet MuenchenMuenchenGermanyParticipant
Tp21 GmbHBerlinGermanyParticipant
Universitatsklinikum BonnBonnGermanyParticipant
University of HamburgHamburgGermanyParticipant
Australo Interinnov Marketing Lab SLMadridSpainParticipant
Stalicla R&d S.l.BarcelonaSpainParticipant
Universidad Politecnica De MadridMadridSpainParticipant
3d-Pharmxchange BVTilburgNetherlandsParticipant
Academisch Ziekenhuis MaastrichtMaastrichtNetherlandsParticipant
Arega Medical Nederland BVBredaNetherlandsParticipant
Machine2learn BVAmstelveenNetherlandsParticipant
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsParticipant
Universidade Do PortoPortoPortugalParticipant
Egnosis SRLSfantu GheorgheRomaniaParticipant
Hander & Hjarna ABTingsrydSwedenParticipant
Region StockholmStockholmSwedenParticipant
Brigham IncBostonUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI